Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 07, 2022
Share
Li Kang Biomedical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 185.64 million compared to TWD 61.55 million a year ago. Revenue was TWD 185.64 million compared to TWD 61.55 million a year ago. Net income was TWD 31.63 million compared to TWD 7.35 million a year ago. Basic earnings per share from continuing operations was TWD 1.1826 compared to TWD 0.2783 a year ago. Diluted earnings per share from continuing operations was TWD 1.1739 compared to TWD 0.2783 a year ago.
For the nine months, sales was TWD 488.85 million compared to TWD 253.39 million a year ago. Revenue was TWD 488.85 million compared to TWD 253.39 million a year ago. Net income was TWD 76 million compared to TWD 29.79 million a year ago. Basic earnings per share from continuing operations was TWD 2.8348 compared to TWD 1.113 a year ago. Diluted earnings per share from continuing operations was TWD 2.8174 compared to TWD 1.1043 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 